Thermionics sales heat up
SPRINGFIELD, Ill. —Thermionics’ ThermiPaq products, which now sport an eye-catching yellow “Control Your Pain!” panel as part of a new graphics package, has been a significant driver of growth within the heat/ice packs segment of late.
For the 52 weeks ended Aug. 8, Thermipaq sales were up 27.2%, reaching $6.1 million across food, drug and mass (minus Walmart) outlets, according to SymphonyIRI Group data. That growth is outpacing the category as a whole, which currently is trending up 6.1%.
In addition to rolling out a new graphics package, Thermionics has been positioning its product line against the chronic pain shopper as an incremental opportunity for retailers. According to recent Thermionics research, 80% of consumers who are treating chronic pain not only purchase multiple solutions across internal analgesics, external rubs, heat/ice therapy and body support devices, but they also shop these sets on a regular basis in search of their own personal pain-relieving regimen of products. There’s an incessant need to find a new or different solution, Thermionics noted, that’s driving consumers toward external analgesic items. That may make for an opportunity to establish a chronic-pain management destination center within the self-care space, the company added, much like there is a destination center at many retailers focused around diabetes-related products.
Larger waists linked to diabetes in new study
NEW YORK A new study published in the Journal of Epidemiology and Community Health found that the nation’s average larger waist circumference is an indicator as to why the diabetes rate in America is higher than the rate in England.
James Smith, corporate chair of economics at the nonprofit organization RAND Corp., and researchers found that American men’s waists were an average of 3 cm (1.5 in.) larger than those of men in England. Similarly, American women’s waists were an average of 5 cm (2 in.) larger than those of women in England.
Analyzing studies about the health and lifestyles of large numbers of people from the United States and England, researchers found no association between higher diabetes rates in the United States based upon such conventional risk factors as age, smoking, socio-economic status or body mass index, the commonly used ratio of height and weight that is used to measure obesity and overweight levels.
"Americans carry more fat around their middle sections than the English, and that was the single factor that explained most of the higher rates of diabetes seen in the United States, especially among American women. Waist size is the missing new risk factor we should be studying," Smith said.
Genzyme again rejects Sanofi buyout offer
CAMBRIDGE, Mass. The board of directors of Genzyme again has rejected a buyout offer by French drug maker Sanofi-Aventis, Genzyme said Thursday.
The biotech company’s board unanimously turned down the hostile offer Sanofi made Monday to acquire Genzyme for $18.5 billion, or $69 per share, saying it was “opportunistic” and undervalued the company.
Specifically, Genzyme said Sanofi’s offer failed to recognize its late-stage development pipeline, which includes three drugs it plans to launch by the end of 2013, including alemtuzumab, a therapy for multiple sclerosis that the company said was “potentially transformative” and had potential to capture a significant share of the global MS market after its 2012 launch. The company also has pursued a plan to cut costs and improve manufacturing and other operations, which it said Sanofi’s deal did not take into account.
Genzyme focuses on therapies to treat such rare, genetic diseases as Fabry disease and Gaucher disease, but shortages of drugs used to treat those diseases –– such as Fabrazyme (agalsidase beta) and Cerezyme (imiglucerase) –– arose last year due to product contamination issues at Genzyme’s manufacturing plants.
If successful, Sanofi’s acquisition of Genzyme would be among the largest in the industry since the wave of high-priced buyouts last year in which Pfizer bought Wyeth, Merck bought Schering-Plough and Roche bought the remaining stock of Genentech that it didn’t already own. In all three cases, the main objective was to gain access to the acquired companies’ significant portfolios and pipelines of specialty drugs, particularly biologics.